A Double Blind Study of the Effect of Tranexamic Acid in Essential Menorrhagia

Vermylen, J; Verhaegen-Declercq, M. L; Verstraete, Marc; Fierens, F

doi:10.1055/s-0038-1651301

Cited by 46 publications

(25 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated beyond reasonable doubt in controlled studies that synthetic fibrinolysis inhibitors can diminish bleeding from areas with increased local fibrinolytic activity as for instance in the urinary tract [1,8,16] and uterus [10,15,20]. The effective oral dose required is approximately 400 mg/kg EACA or between 60-90 mg/kg AMCHA.…”

Section: Discussionmentioning

confidence: 99%

Double Blind Evaluation of the Haemostatic Effect of Adrenochrome Monosemicarbazone, Conjugated Oestrogens and Epsilonaminocaproic Acid after Adenotonsillectomy

1968

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Double Blind Evaluation of the Haemostatic Effect of Adrenochrome Monosemicarbazone, Conjugated Oestrogens and Epsilonaminocaproic Acid after Adenotonsillectomy

1968

View full text Add to dashboard Cite

“…TXA remains an over-the-counter oral medication for this use in Europe with multiple clinical trials confirming the efficacy and safety for this indication. 19,20 Its use expanded in the 1970s to include the treatment of hemophilia as well as in multiple surgical settings for control of bleeding. 21,22 …”

Section: Introductionmentioning

confidence: 99%

Tranexamic Acid Use in Prehospital Uncontrolled Hemorrhage

Huebner

Dorlac

Cribari

2017

Wilderness & Environmental Medicine

View full text Add to dashboard Cite

The use of tranexamic acid (TXA) in the treatment of trauma patients was relatively unexplored until the landmark Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage-2 (CRASH-2) trial in 2010 demonstrated a reduction in mortality with the use of TXA. Although this trial was a randomized, double-blinded, placebo-controlled study incorporating > 20,000 patients, numerous limitations and weaknesses have been described. As a result, additional studies have followed, delineating the potential risks and benefits of TXA administration. A systematic review of the literature to date reveals a mortality benefit of early (ideally < 1 1hour and no later than 3 hours after injury) TXA administration in the treatment of severely injured trauma patients (systolic blood pressure < 90 mm Hg, heart rate > 110). Combined with abundant literature showing a reduction in bleeding in elective surgery, the most significant benefit may be administration of TXA before the patient goes into shock. Those trials that failed to show a mortality benefit of TXA in the treatment of hemorrhagic shock acknowledged that most patients received blood products before TXA administration, thus confounding the results. Although the use of prehospital TXA in the severely injured trauma patient will become more clear with the trauma studies currently underway, the current literature supports the use of prehospital TXA in this high-risk population. We recommend considering a 1 g TXA bolus en route to definitive care in high-risk patients and withholding subsequent doses until hyperfibrinolysis is confirmed by thromboelastography.

show abstract

“…23–33 Studies included women of reproductive age with regular HMB. Duration of the intervention varied from one to six cycles.…”

Section: Introductionmentioning

confidence: 99%

“…In comparison with placebo, tranexamic acid reduced mean MBL from the baseline by 26%–50%, while a 2%–8% reduction was seen in the placebo groups ( P < 0.05) (two studies did not provide the P -value) 25,26,29,31,33. In a randomized, placebo-controlled, double-blind study (n = 187) by Lukes et al,29 MBL declined to less than 80 mL (standard definition of heavy menstrual bleeding) in 43% of menstrual cycles in women receiving 3.9 g of tranexamic acid per day compared with 17% of cycles in women receiving placebo ( P < 0.001).…”

Section: Introductionmentioning

confidence: 99%

Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety

Leminen

Hurskainen²

2012

IJWH

View full text Add to dashboard Cite

Tranexamic acid has proven to be an effective treatment for heavy menstrual bleeding (HMB). It reduces menstrual blood loss (MBL) by 26%–60% and is significantly more effective than placebo, nonsteroidal anti-inflammatory drugs, oral cyclical luteal phase progestins, or oral etamsylate, while the levonorgestrel-releasing intrauterine system reduces MBL more than tranexamic acid. Other treatments used for HMB are oral contraceptives, danazol, and surgical interventions (endometrial ablation and hysterectomy). Medical therapy is usually considered a first-line treatment for idiopathic HMB. Tranexamic acid significantly improves the quality of life of women treated for HMB. The recommended oral dosage is 3.9–4 g/day for 4–5 days starting from the first day of the menstrual cycle. Adverse effects are few and mainly mild. No evidence exists of an increase in the incidence of thrombotic events associated with its use. An active thromboembolic disease is a contraindication. In the US, a history of thrombosis or thromboembolism, or an intrinsic risk for thrombosis or thromboembolism are considered contraindications as well. This review focuses on the efficacy and safety of tranexamic acid in the treatment of idiopathic HMB. We searched for medical literature published in English on tranexamic acid from Ovid Medline, PubMed, and Cinahl. Additional references were identified from the reference lists of articles. Ovid Medline, PubMed, and Cinahl search terms were “tranexamic acid” and “menorrhagia” or “heavy menstrual bleeding.” Searches were last updated on March 25, 2012. Studies with women receiving tranexamic acid for HMB were included; randomized controlled studies with a description of appropriate statistical methodology were preferred. Relevant data on the physiology of menstruation and the pharmacodynamics and pharmacokinetics of tranexamic acid are also included.

show abstract

A Double Blind Study of the Effect of Tranexamic Acid in Essential Menorrhagia

Cited by 46 publications

References 6 publications

Double Blind Evaluation of the Haemostatic Effect of Adrenochrome Monosemicarbazone, Conjugated Oestrogens and Epsilonaminocaproic Acid after Adenotonsillectomy

Double Blind Evaluation of the Haemostatic Effect of Adrenochrome Monosemicarbazone, Conjugated Oestrogens and Epsilonaminocaproic Acid after Adenotonsillectomy

Tranexamic Acid Use in Prehospital Uncontrolled Hemorrhage

Tranexamic acid for the treatment of heavy menstrual bleeding: efficacy and safety

Contact Info

Product

Resources

About